Management of depression in terminally ill patients - a critical review

O. Balaji, K. L. Bairy, N. Veena

Research output: Contribution to journalReview article

Abstract

Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leading to increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3% to 38% for major depression and 1.5-52% for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so that the quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of both very much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selection of components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whether clinical, psychological, spiritual, or social.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number5
DOIs
Publication statusPublished - 01-01-2017
Externally publishedYes

Fingerprint

Terminally Ill
Depression
Neoplasms
Art Therapy
Psychology
Psychological Stress
Quality of Life
Pharmacology
Survival
Mortality
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{adf86dbf4c2d4460ad961a0bfda3ab65,
title = "Management of depression in terminally ill patients - a critical review",
abstract = "Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leading to increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3{\%} to 38{\%} for major depression and 1.5-52{\%} for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so that the quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of both very much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selection of components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whether clinical, psychological, spiritual, or social.",
author = "O. Balaji and Bairy, {K. L.} and N. Veena",
year = "2017",
month = "1",
day = "1",
doi = "10.22159/ajpcr.2017.v10i5.17345",
language = "English",
volume = "10",
pages = "31--36",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "5",

}

Management of depression in terminally ill patients - a critical review. / Balaji, O.; Bairy, K. L.; Veena, N.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 5, 01.01.2017, p. 31-36.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of depression in terminally ill patients - a critical review

AU - Balaji, O.

AU - Bairy, K. L.

AU - Veena, N.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leading to increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3% to 38% for major depression and 1.5-52% for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so that the quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of both very much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selection of components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whether clinical, psychological, spiritual, or social.

AB - Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leading to increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3% to 38% for major depression and 1.5-52% for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so that the quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of both very much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selection of components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whether clinical, psychological, spiritual, or social.

UR - http://www.scopus.com/inward/record.url?scp=85018724695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018724695&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i5.17345

DO - 10.22159/ajpcr.2017.v10i5.17345

M3 - Review article

VL - 10

SP - 31

EP - 36

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 5

ER -